A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jul 2013 Status changed from active, no longer recruiting to completed, based on results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
25 Jun 2013 Results assessing changes in size of lipid particles presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
25 Jun 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met, according to results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com